Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders

作者：Yoshizawa S; Ohyashiki J H; Ohyashiki M; Umezu T; Suzuki K; Inagaki A; Iida S; Ohyashiki K^*

来源：Blood Cancer Journal, 2012, 2: e53.

DOI：10.1038/bcj.2011.51

• multiple myeloma
• plasma miR-92a
• T lymphocytes

Recent studies have demonstrated that one-third of known microRNAs (miRNAs) are stably detectable in plasma. Therefore, we assessed plasma miRNAs to investigate the dynamics of oncomir 17-92a, which is highly expressed in multiple myeloma (MM) patients. The plasma miR-92a level in symptomatic MM patients was significantly downregulated compared with normal subjects (P%26lt;0.0001), regardless of immunoglobulin subtypes or disease stage at diagnosis. In contrast, miR-92a levels in peripheral blood CD8(+) or CD4(+) cells from MM patients were lower than those of normal subjects, and the miR-92a levels of the cells tended to correlate with plasma miR-92a levels. The plasma miR-92a level in the complete remission group became normalized, whereas the partial response (PR) and very good PR groups did not reach the normal range. In smoldering MM, the plasma miR-92a level did not show a significant difference compared with normal subjects. Our findings suggest that measurement of the plasma miR-92a level in MM patients could be useful for initiation of chemotherapy and monitoring disease status, and the level may represent, in part, the T-cell immunity status of these patients.

• 出版日期2012-1
• 单位河北医科大学